SCHEMBL987675

SCHEMBL987675

CCCC(=O)NC(Cc1ccccc1)C(N)=O

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 1/20 0.58
CHRNB2 P17787 1/20 0.58
CHRNB4 P30926 1/20 0.58
CHRNA3 P32297 1/20 0.58
CHRNA4 P43681 1/20 0.58
PARP1 P09874 1/20 0.57
PARP3 Q9Y6F1 1/20 0.57
MMP1 P03956 1/20 0.53
FCER2 P06734 1/20 0.53
CNR1 P21554 2/20 0.53
CNR2 P34972 2/20 0.53
HPGDS O60760 2/20 0.52
FAAH O00519 2/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA9 Q16790 1/20 0.52
ITGB3 P05106 1/20 0.51
ITGA2B P08514 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8258217 1.00 PSMB5 (0.58) PSMB5CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL3147995 0.91 PSMB5 (0.60) PSMB5CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL9666396 0.90 FAAH (0.65) PSMB5FAAHITGB3ITGA2B
SCHEMBL16449189 0.89 PSMB5 (0.60) PSMB5CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5200201 0.89 FAAH (0.67) PSMB5FAAHITGB3ITGA2B
SCHEMBL9664715 0.89 FAAH (0.67) PSMB5FAAHITGB3ITGA2B
SCHEMBL9666046 0.89 FAAH (0.67) PSMB5FAAHITGB3ITGA2B
SCHEMBL9666189 0.89 FAAH (0.67) PSMB5FAAHITGB3ITGA2B
SCHEMBL5200203 0.89 FAAH (0.67) PSMB5FAAHITGB3ITGA2B
SCHEMBL9664236 0.89 FAAH (0.67) PSMB5FAAHITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180878-A1 AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION RHEA INNOVATIONS S.R.L. (IT) 2024-06-06 US claimed
EP-4322935-A1 AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION Rhea Innovations S.R.L. (IT) 2024-02-21 EP claimed
WO-2022219020-A1 AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION RHEA INNOVATIONS S.R.L. (IT) 2022-10-20 WO claimed
US-10034937-B2 Synergistic nutritional compositions and uses thereof MEAD JOHNSON NUTRITION COMPANY (US) 2018-07-31 US claimed
US-20170215464-A1 NUTRITIONAL COMPOSITIONS CONTAINING DIETARY BUTYRATE AND USES THEREOF MEAD JOHNSON NUTRITION COMPANY 2017-08-03 US claimed
US-20170157242-A1 SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF MEAD JOHNSON NUTRITION COMPANY 2017-06-08 US claimed
US-20170127693-A1 NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF MEAD JOHNSON NUTRITION COMPANY 2017-05-11 US claimed
US-9255062-B2 Fatty acid derivatives for oral administration endowed with high palatability RHEA INNOVATIONS S.R.L. (IT) 2016-02-09 US claimed
EP-2268605-B1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY BERNI CANANI ROBERTO (IT) 2014-06-04 EP claimed
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY RHEA INNOVATIONS S.R.L. (IT) 2011-04-28 US claimed
EP-2268605-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY Berni Canani, Roberto (IT) 2011-01-05 EP claimed
WO-2009130735-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY BERNI CANANI ROBERTO (IT) 2009-10-29 WO claimed
US-20240180878-A1 AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION RHEA INNOVATIONS S.R.L. (IT) 2024-06-06 US disclosed
US-20240180878-A1 AMIDE DERIVATIVES OF BUTYRIC ACID FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION RHEA INNOVATIONS S.R.L. (IT) 2024-06-06 US disclosed
CN-117821537-A Method for synthesizing butyric acid sustained release agent FBA by enzyme method 江南大学 2024-04-05 CN disclosed
CN-117821537-A Method for synthesizing butyric acid sustained release agent FBA by enzyme method 江南大学 2024-04-05 CN disclosed
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY RHEA INNOVATIONS S.R.L. (IT) 2011-04-28 US disclosed
EP-2268605-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY Berni Canani, Roberto (IT) 2011-01-05 EP disclosed
WO-2009130735-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY BERNI CANANI ROBERTO (IT) 2009-10-29 WO disclosed
WO-2009130735-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY BERNI CANANI ROBERTO (IT) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY FABP2, FFAR2, VIP PSMB5 1845/4885CHRNB2 1195/4885CHRNB4 1859/4885
US-10034937-B2 Synergistic nutritional compositions and uses thereof FABP2, LRBA, TSLP PSMB5 878/4885CHRNB2 222/4885CHRNB4 257/4885
US-20170157242-A1 SYNERGISTIC NUTRITIONAL COMPOSITIONS AND USES THEREOF FABP2, LRBA, TSLP PSMB5 878/4885CHRNB2 222/4885CHRNB4 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.